{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:36:46Z","timestamp":1770907006217,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T00:00:00Z","timestamp":1500940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81441080"],"award-info":[{"award-number":["81441080"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502023"],"award-info":[{"award-number":["81502023"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201508110083"],"award-info":[{"award-number":["201508110083"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>5\u2010Fluorouracil (5\u2010FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents. However, it frequently causes intestinal mucosal injury and related side effects, such as abdominal pain and diarrhoea, which limit the use of 5\u2010FU in a clinic setting. Polaprezinc has gradually become known as a mucosal protective agent for the management of gastric ulcer. This study aimed to investigate the prophylactic efficacy of Polaprezinc administered orally against intestinal mucositis induced by 5\u2010FU in mice on the condition that the antitumour effect could not be compromised. We induced intestinal mucositis in SPF\u2010grade ICR mice with 5\u2010FU, and evaluated intestinal damage in the absence or presence of Polaprezinc. We examined the score of diarrhoea and the loss of weight after the 5\u2010FU treatment and assessed the integrity of villus and the proliferation of small intestine crypt cells by haematoxylin and eosin staining and PCNA immunohistochemical detection. The antitumour effect of 5\u2010FU on colorectal cancer was assessed with or without Polaprezinc in a xenograft model. The result showed that Polaprezinc significantly reduced the elevated diarrhoea score and the body\u2010weight loss caused by 5\u2010FU abolished histological abnormality and crypt cell hypoproliferation in a dose\u2010dependent manner, without affecting 5\u2010FU efficacy on colon xenograft tumour in mice. We conclude that Polaprezinc could inhibit 5\u2010FU\u2010induced diarrhoea and alleviate the weight loss during 5\u2010FU chemotherapy, as a possible candidate for treatment and prevention of intestinal mucositis, through protecting intestinal mucosa and improving the quality of life after chemotherapy.<\/jats:p>","DOI":"10.1111\/bcpt.12841","type":"journal-article","created":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T14:26:43Z","timestamp":1498919203000},"page":"480-486","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Oral Administration of Polaprezinc Attenuates Fluorouracil\u2010induced Intestinal Mucositis in a Mouse Model"],"prefix":"10.1111","volume":"121","author":[{"given":"Zhaoyang","family":"Liu","sequence":"first","affiliation":[{"name":"Tumor Marker Research Center National Cancer Center\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"Xie","sequence":"additional","affiliation":[{"name":"Jilin Province Broadwell Pharmaceutical Co., Ltd. Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingru","family":"Li","sequence":"additional","affiliation":[{"name":"Jilin Province Broadwell Pharmaceutical Co., Ltd. Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Teng","sequence":"additional","affiliation":[{"name":"Jilin Province Broadwell Pharmaceutical Co., Ltd. Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Liang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Oncology National Cancer Center\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Oncology National Cancer Center\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaogang","family":"Yang","sequence":"additional","affiliation":[{"name":"NSF Nanoscale Science and Engineering Center (NSEC) The Ohio State University Columbus OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobing","family":"Wang","sequence":"additional","affiliation":[{"name":"Tumor Marker Research Center National Cancer Center\/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,7,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.04.006"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2014.05.012"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2013.05.019"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-010-0213-9"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1269\/jrr.07114"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2015.01.004"},{"key":"e_1_2_6_8_1","first-page":"783","article-title":"Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P\u2010AG) for stomatitis induced by Docetaxel\/Cisplatin\/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer","volume":"38","author":"Sugisaki T","year":"2011","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03136.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12331"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12793"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3139-y"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13725"},{"issue":"11","key":"e_1_2_6_14_1","first-page":"43","article-title":"Polaprezinc, a gastroprotective agent: attenuation of monochloramine\u2010evoked gastric DNA fragmentation","volume":"34","author":"Suzuki H","year":"1999","journal-title":"J Gastroenterol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.09056FP"},{"key":"e_1_2_6_16_1","first-page":"581","article-title":"Importance of luminal and mucosal zinc in the mechanism of experimental gastric ulcer healing","volume":"61","author":"Opoka W","year":"2010","journal-title":"J Physiol Pharmacol"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.099929"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-13-108"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2016.983"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2017.1279724"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acthis.2017.03.007"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/134.4.811"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.2903\/j.efsa.2014.3844"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-100102426"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563659809162595"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12011-014-9943-5"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.12841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.12841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T11:14:35Z","timestamp":1695726875000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.12841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,25]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/bcpt.12841"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.12841","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,25]]},"assertion":[{"value":"2017-05-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}